Loading stock data…
GSK PLC ORD 31 1/4P (GSK.L)
LSE1,797pGBX-41.00p (-2.23%)
Market ClosedLast close Sep 8
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GSK plc in the Healthcare sector is trading at 1,796p with a market capitalization of $72.8B. Wall Street consensus targets 2,155p (21 analysts), implying a +19.9% move over the next 12 months. The stock is currently 21% below its 52-week high of 2,282p, remaining 7.8% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +19.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (GBP) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | £7.99B↓ | £8.55B↓ | £8.62B↑ | £7.63B↓ | £8.41B |
| Gross Profit | £5.82B↓ | £6.29B↑ | £5.96B↑ | £5.75B↓ | £6.14B |
| Operating Income | £2.02B↓ | £2.59B↑ | £1.51B↓ | £2.29B↑ | £481.00M |
| Net Income | £1.44B↓ | £2.01B↑ | £636.00M↓ | £1.74B↑ | £435.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
£72.80B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.40
Beta
Defensive asset. Lower volatility than the S&P 500.
0.29
Div Yield
Strong income play. Yield provides a meaningful total return floor.
366.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
33.38%
Volume
Today's trading volume
1,697
Recent News
The Shingles Vaccine Is $0 at the Pharmacy. Get the Same Shot at Your Doctor’s Office and the Front Desk Asks for $200 Per Dose.
The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has a gap, and most patients have no idea it exists until they're already holding the receipt.
Can GSK’s Hepatitis B Breakthrough Become a £2 Billion Opportunity?
GSK plc (NYSE:GSK) has reached two important regulatory milestones involving treatments for chronic hepatitis B and rectal cancer. Bepirovirsen, which is now branded as Hibsago, was approved by Japan, marking the drug’s first authorization anywhere in the world. In a separate development, the FDA granted priority review to an application seeking approval of GSK’s (NYSE:GSK) […]
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.